Inflammasomes and intestinal homeostasis: regulating and connecting infection, inflammation and the microbiota.
暂无分享,去创建一个
[1] E. Elinav,et al. NLRP6 Inflammasome Orchestrates the Colonic Host-Microbial Interface by Regulating Goblet Cell Mucus Secretion , 2014, Cell.
[2] Zihai Li,et al. Inflammasome activation plays an important role in the development of spontaneous colitis , 2016 .
[3] S. Nordlander,et al. NLRC4 expression in intestinal epithelial cells mediates protection against an enteric pathogen , 2013, Mucosal Immunology.
[4] K. Maloy,et al. Nlrp3 Activation in the Intestinal Epithelium Protects against a Mucosal Pathogen , 2013, Mucosal Immunology.
[5] R. Flavell,et al. Interactions between Nod-Like Receptors and Intestinal Bacteria , 2013, Front. Immunol..
[6] M. Idzko,et al. The Nlrp3 inflammasome regulates acute graft-versus-host disease , 2013, The Journal of experimental medicine.
[7] D. Powell,et al. Cytoplasmic LPS Activates Caspase-11: Implications in TLR4-Independent Endotoxic Shock , 2013, Science.
[8] M. T. Wong,et al. Noncanonical Inflammasome Activation by Intracellular LPS Independent of TLR4 , 2013, Science.
[9] E. Elinav,et al. Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer , 2013, Proceedings of the National Academy of Sciences.
[10] Daniel E. Zak,et al. Caspase-11 Protects Against Bacteria That Escape the Vacuole , 2013, Science.
[11] H. Lehr,et al. Protective and Aggravating Effects of Nlrp3 Inflammasome Activation in IBD Models: Influence of Genetic and Environmental Factors , 2012, Digestive Diseases.
[12] R. Flavell,et al. Life, death, and miracles: Th17 cells in the intestine , 2012, European journal of immunology.
[13] Francis J. Huber,et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine , 2012, Nature.
[14] E. Elinav,et al. Inflammasomes: far beyond inflammation , 2012, Nature Immunology.
[15] Richard A. Flavell,et al. Inflammasomes in health and disease , 2012, Nature.
[16] J. Sauer,et al. Innate immune pathways triggered by Listeria monocytogenes and their role in the induction of cell-mediated immunity. , 2012, Advances in immunology.
[17] Jinfeng Liu,et al. Non-canonical inflammasome activation targets caspase-11 , 2011, Nature.
[18] K. Fitzgerald,et al. The PYHIN protein family as mediators of host defenses , 2011, Immunological reviews.
[19] A. Aderem,et al. Caspase‐1‐induced pyroptotic cell death , 2011, Immunological Reviews.
[20] M. Gale,et al. RIG-I Like Receptors in Antiviral Immunity and Therapeutic Applications , 2011, Viruses.
[21] Richard A. Flavell,et al. NLRP6 Inflammasome Regulates Colonic Microbial Ecology and Risk for Colitis , 2011, Cell.
[22] Y. Wan,et al. Memory/effector (CD45RBlo) CD4 T cells are controlled directly by IL-10 and cause IL-22–dependent intestinal pathology , 2011, The Journal of experimental medicine.
[23] E. Miao,et al. Salmonella and Caspase-1: A complex Interplay of Detection and Evasion , 2011, Front. Microbio..
[24] E. Elinav,et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4 , 2010, Proceedings of the National Academy of Sciences.
[25] F. Marincola,et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18 , 2010, The Journal of experimental medicine.
[26] F. Sutterwala,et al. A Yersinia effector protein promotes virulence by preventing inflammasome recognition of the type III secretion system. , 2010, Cell host & microbe.
[27] J. Tschopp,et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome , 2010, Gut.
[28] M. Kastan,et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. , 2010, Immunity.
[29] N. Beauchemin,et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. , 2010, Immunity.
[30] J. Tschopp,et al. The Inflammasomes , 2010, Cell.
[31] A. Murphy,et al. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. , 2008, Immunity.
[32] Lois J. Maltais,et al. The NLR gene family: a standard nomenclature. , 2008, Immunity.
[33] A. Murphy,et al. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. , 2007, Immunity.
[34] T. Ma,et al. IL-1β Causes an Increase in Intestinal Epithelial Tight Junction Permeability1 , 2007, The Journal of Immunology.
[35] H. Lehr,et al. The ICE Inhibitor Pralnacasan Prevents DSS-Induced Colitis in C57BL/6 Mice and Suppresses IP-10 mRNA but Not TNF-α mRNA Expression , 2007, Digestive Diseases and Sciences.
[36] T. Pizarro,et al. Commentary: The role of the IL‐18 system and other members of the IL‐1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe? , 2004, European journal of immunology.
[37] H. Lehr,et al. The Interleukin-1β-Converting Enzyme Inhibitor Pralnacasan Reduces Dextran Sulfate Sodium-Induced Murine Colitis and T Helper 1 T-Cell Activation , 2004, Journal of Pharmacology and Experimental Therapeutics.
[38] H. Lehr,et al. The interleukin-1 beta-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. , 2004, The Journal of pharmacology and experimental therapeutics.
[39] S. Akira,et al. Contrasting action of IL-12 and IL-18 in the development of dextran sodium sulphate colitis in mice. , 2003, Scandinavian journal of gastroenterology.
[40] J. Derry,et al. Inflammation and Inflammatory Bowel Disease , 2022 .
[41] G. Fantuzzi,et al. IL-1β-converting enzyme (caspase-1) in intestinal inflammation , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[42] G. Fantuzzi,et al. IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[43] R. Sartor,et al. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. , 1994, Gastroenterology.